News

Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
Wegovy maker Novo Nordisk warns on continued copycat-drug challenge as new CEO readied
Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...
Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason.
Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by Eli Lilly as just one ...
Novo Nordisk reports second quarter earnings missing Wall Street estimates on slower GLP-1 sales
Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.
Prothena Gains on Novo Nordisk Plans to Advance Protein-Disorder Treatment
Shares of Prothena climbed after Novo Nordisk said during its second-quarter earnings call that it expects to advance a treatment for amyloidosis it bought from Prothena in 2021. The Dublin company's ...
These Stocks Are Moving the Most Today: Super Micro, AMD, Snap, Novo Nordisk, McDonald’s, Disney, Match, and More
Super Micro, AMD, and Snap stocks tumbled after quarterly earnings reports. Arista and Disney stocks were rising.
Novo Nordisk: I Was Wrong Twice, But This Selloff Looks Like 2016 All Over Again
Novo Nordisk is attractively valued after the sell-off, but near-term recovery requires patience. Read why I'm downgrading ...
Novo Nordisk to advance ATTR amyloidosis mAb to Phase III
Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials.